Lists of preferred terms

Orthostatic hypotension
Blood osmolarity increased, blood pressure ambulatory decreased, blood pressure decreased, blood pressure diastolic decreased, blood pressure immeasurable, blood pressure orthostatic abnormal, blood pressure orthostatic decreased, blood pressure systolic decreased, blood pressure systolic inspiratory decreased, central venous pressure decreased, circulatory collapse, decreased ventricular preload, diastolic hypotension, hypotension, mean arterial pressure decreased, orthostatic heart rate response increased, orthostatic hypotension

Search strategy

Embase query
#1 diabetes AND mellitus OR (type AND 2 AND diabetes) OR (type AND ii AND diabetes)
#2 sodium AND glucose AND cotransporter AND 2 AND inhibitor OR (sodium AND glucose AND transporter AND 2 AND inhibitor*) OR (sodium AND glucose AND transporter AND ii AND inhibitor*) OR (sglt2 AND inhibitor*)
#3 canagliflozin OR dapagliflozin OR empagliflozin OR ertugliflozin OR tofogliflozin OR ipragliflozin OR remogliflozin
#4 randomi*ed AND controlled AND trial OR (randomi*ed AND trial)
#5 #2 OR #3
#6 #1 AND #4 AND #5

CENTRAL query
(Diabetes mellitus or type 2 diabetes or type ii diabetes):ti,ab,kw AND (sodium glucose transporter 2 inhibitor* or sodium glucose transporter ii inhibitor* or SGLT2 inhibitor):ti,ab,kw AND (Canagliflozin or Dapagliflozin or Empagliflozin or Ertugliflozin or Tofogliflozin or Ipragliflozin or Remogliflozin):ti,ab,kw (Word variations have been searched)

Pubmed query
#20 Search ((((((((((((((Sodium glucose co-transporter) OR (((SGLT2) OR SGLT-2) OR SGLT 2)) OR (((Tofogliflozin) OR Apleway) OR Deberza) OR CSG452)) OR ((Empagliflozin) OR Jardiance)) OR (((dapagliflozin) OR Farxiga) OR Forxiga)) OR ((Canagliflozin OR Invokana)) OR ((Sotagliflozin) OR LX4211)) OR ((luseogliflozin) OR Lusefi)) OR ((ipragliflozin) OR Suglat)) OR ((remogliflozin) OR BHVO91009)) OR ((sergliflozin) OR GW869682X)) OR (((ertugliflozin) OR MK-8835) OR PF-04971729))) AND (((random*) OR Randomized Controlled Trial[Publication Type]) OR ((RCT) OR RCTs))) AND (((Diabetes mellitus) OR type 2 diabetes) OR type ii diabetes)
#19 Search ((Diabetes mellitus) OR type 2 diabetes) OR type ii diabetes
#18 Search ((random*) OR Randomized Controlled Trial[Publication Type]) OR ((RCT) OR RCTs))
#17 Search (RCT) OR RCTs
#16 Search Randomized Controlled Trial[Publication Type]
#15 Search random*
#14 Search (((((((((sodium glucose co-transporter) OR (((SGLT2) OR SGLT-2) OR sglt 2)) OR (((tologliflozin) OR apleway) OR deberza) OR CSG452)) OR ((empagliflozin) OR jardiance)) OR (((dapagliflozin) OR farxiga) OR forxiga)) OR ((canagliflozin) OR invokana)) OR ((ertugliflozin) OR MK-8835) OR PF-04971729))) AND (((random*) OR RCTs))) AND (((Diabetes mellitus) OR type 2 diabetes) OR type ii diabetes)
#1 Search ((ertugliflozin) OR MK-8835) OR PF-04971729
#10 Search (remogliflozin) OR BHV091009
#9 Search (ipragliflozin) OR Suglat
#8 Search (luseogliflozin) OR Lusefi
#7 Search (Sotagliflozin) OR LX4211
#6 Search (Canagliflozin) OR Invokana
#5 Search ((dapagliflozin) OR Farxiga) OR Forxiga
#4 Search (Empagliflozin) OR Jardiance
#3 Search (((Tofogliflozin) OR Apleway) OR Deberza) OR CSG452
#2 Search ((SGLT2) OR SGLT-2) OR SGLT 2
#1 Search Sodium glucose co-transporter

**Result of trim-and-fill method**

Meta-analysis

| Method  | Pooled Est | 95% CI | Asymptotic z_value | Asymptotic p_value | No. of studies |
|---------|------------|--------|-------------------|-------------------|----------------|
| Fixed   | 0.154      | 0.432  | 0.739             | 0.515             | 0.606          |
| Random  | 0.154      | 0.432  | 0.739             | 0.515             | 0.606          |

Test for heterogeneity: Q= 9.168 on 15 degrees of freedom (p= 0.869)

Moment-based estimate of between studies variance = 0.000

Trimming estimator: Linear

Meta-analysis type: Fixed-effects model

| iteration | estimate | Tn | # to trim | diff |
|-----------|----------|----|-----------|------|
| 1         | 0.154    | 61 | 0         | 136  |
| 2         | 0.154    | 61 | 0         | 0    |

Note: no trimming performed; data unchanged

Filled

Meta-analysis (exponential form)
### Pooled 95% CI Asymptotic No. of studies

| Method | Est    | Lower  | Upper  | z_value | p_value | studies |
|--------|--------|--------|--------|---------|---------|---------|
| Fixed  | 1.166  | 0.650  | 2.094  | 0.515   | 0.606   | 16      |
| Random | 1.166  | 0.650  | 2.094  | 0.515   | 0.606   |

Test for heterogeneity: Q = 9.168 on 15 degrees of freedom (p = 0.869)

Moment-based estimate of between studies variance = 0.000

**Result of subgroup analysis of background treatment**

| Study or Subgroup | Interventions | Control | Weight | Risk Ratio M-H, Random, 95% CI | Risk Ratio M-H, Random, 95% CI |
|-------------------|---------------|---------|--------|-------------------------------|-------------------------------|
| Bailey 2010       | 2 409         | 1 137   | 6.8%   | 0.87 [0.86, 0.93]             |                               |
| Cefalu 2013       | 1 998         | 0 482   | 3.3%   | 1.59 [0.98, 2.68]             |                               |
| Llave-Martin 2013 | 0 736         | 1 386   | 3.4%   | 0.17 [0.01, 1.07]             |                               |
| Subtotal (95% CI) | 2141          | 985     | 12.7%  | 0.57 [0.11, 2.69]             |                               |

Total events 5 2

Heterogeneity: Tau² = 0.00; Chi² = 2.20; df = 2 (p = 0.39); I² = 0%

Test for overall effect: Z = 1.23 (p = 0.22)

| Study or Subgroup | Interventions | Control | Weight | Risk Ratio M-H, Random, 95% CI | Risk Ratio M-H, Random, 95% CI |
|-------------------|---------------|---------|--------|-------------------------------|-------------------------------|
| Bailey 2010       | 1 198         | 0 75    | 4.9%   | 0.38 [0.22, 0.65]             |                               |
| Intaglioli 2014   | 2 176         | 0 93    | 3.7%   | 2.63 [1.34, 5.14]             |                               |
| Knia 2014         | 1 172         | 0 56    | 3.4%   | 0.69 [0.24, 2.37]             |                               |
| Schmieder 2013    | 2 392         | 0 192   | 3.7%   | 2.43 [1.02, 3.30]             |                               |
| Tilkic 2015       | 0 652         | 1 271   | 3.4%   | 0.36 [0.01, 1.01]             |                               |
| Subtotal (95% CI) | 1494          | 687     | 18.7%  | 0.83 [0.21, 3.26]             |                               |

Total events 6 2

Heterogeneity: Tau² = 0.00; Chi² = 2.20; df = 2 (p = 0.39); I² = 0%

Test for overall effect: Z = 0.27 (p = 0.79)

| Study or Subgroup | Interventions | Control | Weight | Risk Ratio M-H, Random, 95% CI | Risk Ratio M-H, Random, 95% CI |
|-------------------|---------------|---------|--------|-------------------------------|-------------------------------|
| Boden 2013        | 3 477         | 0 237   | 3.9%   | 3.49 [1.18, 16.76]            |                               |
| Inoue 2010        | 1 24          | 0 24    | 3.4%   | 3.09 [1.13, 3.09]             |                               |
| McKinnon 2015     | 2 373         | 5 271   | 12.8%  | 0.40 [0.08, 2.08]             |                               |
| Merzen 2010       | 1 302         | 0 311   | 3.4%   | 3.09 [0.13, 23.30]            |                               |
| Yale 2013         | 1 176         | 0 90    | 3.4%   | 1.62 [0.36, 6.86]             |                               |
| Subtotal (95% CI) | 3355          | 3033    | 26.8%  | 1.08 [0.35, 3.35]             |                               |

Total events 8 5

Heterogeneity: Tau² = 0.00; Chi² = 0.39; df = 4 (p = 0.87); I² = 0%

Test for overall effect: Z = 0.14 (p = 0.89)

Total (95% CI) 7595 5234 100.0% 1.17 [0.66, 2.09]

Total events 28 15

Heterogeneity: Tau² = 0.00; Chi² = 0.17; df = 16 (p = 0.87); I² = 0%

Test for overall effect: Z = 0.52 (p = 0.82)

Test for subgroup differences: X² = 1.50; df = 3 (p = 0.62); I² = 0%